Search by Drug Name or NDC
NDC 65862-0670-05 Repaglinide 0.5 mg/1 Details
Repaglinide 0.5 mg/1
Repaglinide is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is REPAGLINIDE.
MedlinePlus Drug Summary
Repaglinide is used to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Repaglinide helps your body regulate the amount of glucose (sugar) in your blood. It decreases the amount of glucose by stimulating the pancreas to release insulin. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems.Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 65862-0670-05Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Repaglinide
Product Information
| NDC | 65862-0670 |
|---|---|
| Product ID | 65862-670_7a7b883a-ccb0-4037-87a9-d64e5ab5d4c5 |
| Associated GPIs | 27280060000310 |
| GCN Sequence Number | 038906 |
| GCN Sequence Number Description | repaglinide TABLET 0.5 MG ORAL |
| HIC3 | C4K |
| HIC3 Description | ANTIHYPERGLYCEMIC, INSULIN-RELEASE STIMULANT TYPE |
| GCN | 26311 |
| HICL Sequence Number | 017915 |
| HICL Sequence Number Description | REPAGLINIDE |
| Brand/Generic | Generic |
| Proprietary Name | Repaglinide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Repaglinide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 0.5 |
| Active Ingredient Units | mg/1 |
| Substance Name | REPAGLINIDE |
| Labeler Name | Aurobindo Pharma Limited |
| Pharmaceutical Class | Glinide [EPC], Potassium Channel Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA203820 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 65862-0670-05 (65862067005)
| NDC Package Code | 65862-670-05 |
|---|---|
| Billing NDC | 65862067005 |
| Package | 500 TABLET in 1 BOTTLE (65862-670-05) |
| Marketing Start Date | 2014-01-22 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |